黄芪甲苷通过抑制PKC/MAPK通路修复损伤人足细胞裂孔膜
Astragaloside Ⅳ Repairs the Damage of Human Podocyte Slit Diaphragm by Restraining PKC/MAPK Pathway
-
摘要: 探讨核苷酸嘌呤霉素对人足细胞的损伤作用及黄芪甲苷的修复作用，并探索PKC/MAPK通路是否参与其中，寻找可能存在的作用机制。方法 用CCK-8法筛选合适的核苷酸嘌呤霉素造模浓度及黄芪甲苷的最大无毒浓度，予核苷酸嘌呤霉素刺激人足细胞造成损伤，予不同浓度的黄芪甲苷处理后，应用Western blot法检测nephrin、podocin、PKC、JNK及p38蛋白水平的表达情况。结果 核苷酸嘌呤霉素刺激后，nephrin、podocin的蛋白的表达明显降低，而PKC、JNK、p38的表达明显上升，用药后渐趋正常，且呈浓度依赖性，差异有统计学意义（P＜0.05），溶剂对照组无明显改变，无统计学差异（P＞0.05）。结论 核苷酸嘌呤霉素能造成人足细胞裂孔膜损伤，黄芪甲苷对这种损伤有修复作用，而PKC/MAPK通路参与修复过程，同时这种修复作用与黄芪甲苷浓度呈正相关。
-
关键词:
- 黄芪甲苷 /
- 人足细胞 /
- nephrin /
- podocin /
- PKC/MAPK通路
Abstract: OBJECTIVE To investigate the damage effects of puromycin aminonucleoside (PAN) on human podocyte and the repair effect of astragaloside Ⅳ. At the same time，to explore whether PKC/MAPK pathway is involved in it to seek possible mechanisms. METHODS To filter appropriate concentration of model establishment of PAN and the maximum non-toxic concentration of astragaloside Ⅳ by cytotoxicity test CCK-8.In the experiment，PAN was used to cause the damage of human podocytes and then different concentrations of astragaloside Ⅳ was treated with cells.Finally，the protein expression levels of nephrin， podocin， PKC， JNK and p38 were detected by Western blotting. RESULTS The protein expression levels of nephrin and podocin were declined as where as PKC， JNK and p38 were ascended obviously after stimulating by PAN and tended to nomal gradually after treatment with astragaloside Ⅳ，furthermore，these changes were in a dose-dependent manner.The difference was statistically significant (P<0.05).However，the changes between solvent control group and model group were unconspicuous， which showed no significant difference. CONCLUSION PAN can cause the damage of human podocyte slit diaphragm and astragaloside Ⅳ can repair the injury which is positively correlated with astragaloside Ⅳ. Meanwhile， PKC/MAPK pathway is involved in the repair process.This may be the possible mechanism of Astragaloside Ⅳ on the repair of human podocyte.-
Keywords:
- astragaloside Ⅳ /
- human podocyte /
- nephrin /
- podocin /
- PKC/MAPK pathway
-
-
期刊类型引用(11)
1. 王宇航，尹凤婷，刘慧强，闫广利，孙晖，王喜军. 复方肾华片及组方中药的有效成分对肾脏保护作用研究进展. 中国现代中药. 2025(02): 381-392 . 
百度学术
2. 郭陈成，张君. 中医治疗足细胞损伤的研究进展. 中国民间疗法. 2024(03): 109-112 . 百度学术
3. 李斌斌，林晓蒙，何俊，张荣荣，毛青云，钟光辉. 黄芪治疗IgA肾病的研究进展. 浙江中西医结合杂志. 2024(04): 380-383 . 百度学术
4. 陈婷，刘伟，黄菲. 基于络病理论探讨益气养阴通络法治疗糖尿病肾脏病. 河南中医. 2024(08): 1173-1177 . 百度学术
5. 邓丽娥，何世东，卢汉祺，姚淑焕，洪嘉玲，李强. 益肾方对慢性肾脏病2～3期患者的疗效及机制分析. 中医临床研究. 2023(16): 52-56 . 百度学术
6. 王泉蓉，于洪洁. 益气通络消癥方对糖尿病肾病患者肾功能及尿液足细胞损伤标志物的影响. 临床与病理杂志. 2023(03): 469-476 . 百度学术
7. 徐进，蒋春波. 黄芪甲苷治疗肾病的药理作用研究进展. 环球中医药. 2022(03): 531-536 . 百度学术
8. 涂海涛，黎颖，宋娜，罗苑苑，周鑫，沈创鹏. 健脾养阴固涩方对糖尿病肾病气阴两虚证患者临床疗效及足细胞的保护作用. 中国实验方剂学杂志. 2022(09): 103-109 . 百度学术
9. 孙雪艳，赵文景，刘志强，沈存，王悦芬，王玉锋，王亚伟. 保肾通络方对糖尿病肾病Ⅲ～Ⅳ期患者临床疗效及足细胞损伤的影响. 环球中医药. 2020(01): 153-156 . 百度学术
10. 凌舒艺，李雨彦，祁爱蓉. 李顺民教授辨治肾性血尿的临床经验介绍. 世界中西医结合杂志. 2020(09): 1650-1653+1671 . 百度学术
11. 曾又佳，贺良平，张冰. 黄芪甲苷通过调控肾素原受体-自噬途径改善嘌呤霉素诱导肾足细胞骨架损伤的作用研究. 中国中医基础医学杂志. 2020(10): 1479-1483 . 百度学术
其他类型引用(4)
计量
- 文章访问数: 1632
- HTML全文浏览量: 12
- PDF下载量: 1188
- 被引次数: 15
下载:
